Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aslan Pharmaceuticals Pte. Ltd.

www.aslanpharma.com

Latest From Aslan Pharmaceuticals Pte. Ltd.

Asia Deal Watch: ASLAN, Bukwang Establish Immuno-Oncology JV In Singapore

The JV to be called JAGUAHR Therapeutics will focus on the AhR pathway. Simcere acquires Chinese rights to JW’s gout candidate.

Deals Business Strategies

Brighter News For Varlitinib As Results In Tough Cancer Type Encourage ASLAN

Following a major setback in another indication earlier this year, ASLAN’s lead asset is now seen as a potential new option for second-line use in biliary tract cancer following promising new data from a Chinese trial.

Clinical Trials Cancer

Asia Executives On The Move: Returners And Leavers At Merck; Changes At Takeda, Ono, Simcere And More

Merck China former R&D head returns after a short stint with startup Ascletis, and Takeda has a new center director for commercial health. Top executives change also take place at Ono in Korea and Simcere Pharma.

Asia Pacific Appointments

Asia Deal Watch: Everest Licenses Asia Rights To Calliditas’ IgA Nephropathy Candidate

While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.

Business Strategies Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • Southeast Asia
        • Singapore
  • Parent & Subsidiaries
  • Aslan Pharmaceuticals Pte. Ltd.
  • Senior Management
  • Carl Firth, PhD, CEO
    Chih-Yi Hsieh, MD, Acting CMO
    Jeff Tomlinson, CBO
    Kiran Asarpota, VP, Fin.
    Mark McHale, PhD, Chief Dev. Officer, Head, R&D
  • Contact Info
  • Aslan Pharmaceuticals Pte. Ltd.
    Phone: 6222 4235
    83 Clemenceau Ave. #12-03
    UE Square
    , 239920
    Singapore
Advertisement
Advertisement
UsernamePublicRestriction

Register